Literature DB >> 3322904

Role of glucagon suppression on gluconeogenesis during insulin treatment of the conscious diabetic dog.

R W Stevenson1, P E Williams, A D Cherrington.   

Abstract

In seven insulin-deficient (less than 3 mU/l) pancreatectomised dogs, the direct and glucagon-related indirect effects of intraportal insulin infusion (350 microU/kg-min; 12 +/- 1 mU/l) on glucose production were determined. Insulin was infused for 300 min during which time the plasma glucagon concentration was allowed to fall (314 +/- 94 to 180 +/- 63 ng/l) for 150 min before being replaced by an infusion intraportally at 2.6 ng/kg-min (323 +/- 61 ng/l) for the remaining 150 min. Glucose production and gluconeogenesis were determined using arterio-venous difference and tracer techniques. Insulin infusion shut off net hepatic glucose output and caused the plasma glucose, blood glycerol and plasma non-esterified fatty acid levels to fall. It caused the hepatic fractional extraction of alanine (0.41 +/- 0.10 to 0.21 +/- 0.06) and lactate (0.32 +/- 0.09 to 0.04 +/- 0.03) to fall which increased their concentrations. When glucagon was replaced, all of these changes were fully or partly reversed with the exception of the changes in glycerol and nonesterified fatty acids. Indeed, 70% of the fall in hepatic glucose production and virtually 100% of the changes in lactate and alanine metabolism produced by basal insulin infusion were mediated by a fall in glucagon. However, the fall in hepatic uptake of glycerol was unaffected by changes in glucagon and thus gluconeogenesis from this substrate was inhibited by insulin per se probably as a result of reduced lipolysis. The latter effect of insulin may explain the incomplete restoration of hepatic glucose production when hyperglucagonaemia was re-established during insulin infusion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3322904     DOI: 10.1007/BF00275744

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  38 in total

1.  Red cell carriage of label: its limiting effect on the exchange of materials in the liver.

Authors:  C A Goresky; G G Bach; B E Nadeau
Journal:  Circ Res       Date:  1975-02       Impact factor: 17.367

2.  Effect of insulin on utilization and production of circulating glucose.

Authors:  J S WALL; R STEELE; R C DE BODO; N ALTSZULER
Journal:  Am J Physiol       Date:  1957-04

3.  Gluconeogenesis from alanine in normal postabsorptive man. Intrahepatic stimulatory effect of glucagon.

Authors:  J L Chiasson; J E Liljenquist; B C Sinclair-Smith; W W Lacy
Journal:  Diabetes       Date:  1975-06       Impact factor: 9.461

4.  A rapid method for the determination of glycogen content and radioactivity in small quantities of tissue or isolated hepatocytes.

Authors:  T M Chan; J H Exton
Journal:  Anal Biochem       Date:  1976-03       Impact factor: 3.365

Review 5.  Gluconeogenesis: methodological approaches in vivo.

Authors:  J L Chiasson; J E Liljenquist; W W Lacy; A S Jennings; A D Cherrington
Journal:  Fed Proc       Date:  1977-02

Review 6.  Hepatic vascular bed.

Authors:  C V Greenway; R D Stark
Journal:  Physiol Rev       Date:  1971-01       Impact factor: 37.312

7.  Use of glucose uptake and glucose clearance for the evaluation of insulin action in vivo.

Authors:  I Gottesman; L Mandarino; J Gerich
Journal:  Diabetes       Date:  1984-02       Impact factor: 9.461

8.  Characteristics of an amino acid transport system in rat liver for glutamine, asparagine, histidine, and closely related analogs.

Authors:  M S Kilberg; M E Handlogten; H N Christensen
Journal:  J Biol Chem       Date:  1980-05-10       Impact factor: 5.157

9.  Dichloroacetate--its in vivo effects on carbohydrate metabolism in the conscious dog.

Authors:  M P Diamond; R C Rollings; L Erlendson; P E Williams; W W Lacy; D Rabin; A D Cherrington
Journal:  Diabetes       Date:  1980-09       Impact factor: 9.461

10.  Importance of glucagon in mediating epinephrine-induced hyperglycemia in alloxan-diabetic dogs.

Authors:  G Perez; F W Kemmer; H L Lickley; M Vranic
Journal:  Am J Physiol       Date:  1981-10
View more
  8 in total

Review 1.  Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover.

Authors:  Roger H Unger; Alan D Cherrington
Journal:  J Clin Invest       Date:  2012-01-03       Impact factor: 14.808

Review 2.  Physiologic action of glucagon on liver glucose metabolism.

Authors:  C J Ramnanan; D S Edgerton; G Kraft; A D Cherrington
Journal:  Diabetes Obes Metab       Date:  2011-10       Impact factor: 6.577

3.  Diabetogenic role of insulin's counterregulatory hormones in the isletectomized, diabetic goby.

Authors:  J T Haigwood; R M Flores; R Mazloumi; G Ngan; K M Kelley
Journal:  Endocrine       Date:  2000-12       Impact factor: 3.633

4.  Insulin signaling is required for insulin's direct and indirect action on hepatic glucose production.

Authors:  Simon J Fisher; C Ronald Kahn
Journal:  J Clin Invest       Date:  2003-02       Impact factor: 14.808

5.  Importance of peripheral insulin levels for insulin-induced suppression of glucose production in depancreatized dogs.

Authors:  A Giacca; S J Fisher; Z Q Shi; R Gupta; H L Lickley; M Vranic
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 6.  Animal models of obesity and diabetes mellitus.

Authors:  Maximilian Kleinert; Christoffer Clemmensen; Susanna M Hofmann; Mary C Moore; Simone Renner; Stephen C Woods; Peter Huypens; Johannes Beckers; Martin Hrabe de Angelis; Annette Schürmann; Mostafa Bakhti; Martin Klingenspor; Mark Heiman; Alan D Cherrington; Michael Ristow; Heiko Lickert; Eckhard Wolf; Peter J Havel; Timo D Müller; Matthias H Tschöp
Journal:  Nat Rev Endocrinol       Date:  2018-01-19       Impact factor: 43.330

7.  Glucagon as a critical factor in the pathology of diabetes.

Authors:  Dale S Edgerton; Alan D Cherrington
Journal:  Diabetes       Date:  2011-02       Impact factor: 9.461

8.  Glucagon-producing cells are increased in Mas-deficient mice.

Authors:  Janaína Felix Braga; Daniela Ravizzoni Dartora; Natalia Alenina; Michael Bader; Robson Augusto Souza Santos
Journal:  Endocr Connect       Date:  2016-12-20       Impact factor: 3.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.